Systemic therapy for metastatic renal-cell carcinoma

TK Choueiri, RJ Motzer - New England Journal of Medicine, 2017 - Mass Medical Soc
Kidney cancers have been extensively studied, and insights from an increased
understanding of tumor biology have led to increases in survival rates. Therapies aimed at …

Clinical review on the management of metastatic renal cell carcinoma

J Tran, MC Ornstein - JCO Oncology Practice, 2022 - ascopubs.org
Renal cell carcinomas vary considerably in their tumor biology and disease course, which is
reflected in the range of treatment paradigms in localized and metastatic renal cell …

Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology

RJ Motzer, E Jonasch, N Agarwal, A Alva… - Journal of the National …, 2022 - jnccn.org
The NCCN Guidelines for Kidney Cancer focus on the screening, diagnosis, staging,
treatment, and management of renal cell carcinoma (RCC). Patients with relapsed or stage …

Kidney cancer, version 2.2017, NCCN clinical practice guidelines in oncology

RJ Motzer, E Jonasch, N Agarwal, S Bhayani… - Journal of the National …, 2017 - jnccn.org
The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the
clinical management of patients with clear cell and non–clear cell renal carcinoma. These …

Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity

B Shuch, A Amin, AJ Armstrong, JN Eble, V Ficarra… - European urology, 2015 - Elsevier
Context Once believed to represent a uniform malignant phenotype, renal cell carcinoma
(RCC) is now viewed as a diverse group of cancers that arise from the nephron. Objective …

Systemic therapy for non–clear cell renal cell carcinomas: a systematic review and meta-analysis

FE Vera-Badillo, AJ Templeton, I Duran, A Ocana… - European urology, 2015 - Elsevier
Context Clinical data supporting the use of targeted agents for the treatment of metastatic
renal cell carcinoma (RCC) are based predominantly on patients with clear cell histology …

Cabozantinib as first-line treatment in patients with metastatic collecting duct renal cell carcinoma: Results of the BONSAI trial for the Italian network for research in …

G Procopio, P Sepe, M Claps, S Buti… - JAMA …, 2022 - jamanetwork.com
Importance Metastatic collecting duct carcinoma (mCDC) is a rare type of non–clear cell
renal cell carcinoma (ncRCC) with poor prognosis and no standard treatments. Despite …

[PDF][PDF] Renal cell carcinoma of variant histology: biology and therapies

P Msaouel, G Genovese, NM Tannir - Hematology/oncology clinics of North …, 2023 - Elsevier
The term variant histology renal cell carcinomas (vhRCC), also known as non-clear cell
RCCs, refers to a diverse group of malignancies with distinct biologic and therapeutic …

Characterization of clinical cases of collecting duct carcinoma of the kidney assessed by comprehensive genomic profiling

SK Pal, TK Choueiri, K Wang, D Khaira, JA Karam… - European urology, 2016 - Elsevier
Background Collecting duct carcinoma (CDC) is a rare type of renal cell carcinoma (RCC)
originating from the renal medulla. Clinical outcomes are poor, and there are no consensus …

Carcinoma of the collecting ducts of Bellini and renal medullary carcinoma: clinicopathologic analysis of 52 cases of rare aggressive subtypes of renal cell carcinoma …

R Gupta, A Billis, RB Shah, H Moch… - The American journal …, 2012 - journals.lww.com
Carcinoma of the collecting ducts of Bellini and renal medullary carcinoma are rare
aggressive neoplasms of putative distal nephron origin. First described in 1949, case reports …